JP Morgan Chase
INDV icon

JP Morgan Chase’s Indivior Pharmaceuticals INDV Stock Holding History

JP Morgan Chase’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Buy
539,863
+328,655
+156% +$10.9M ﹤0.01% 2296
2025
Q4 		$7.58M Buy
211,208
+3,620
+2% +$111K ﹤0.01% 2949
2025
Q3 		$5M Sell
207,588
-183,798
-47% -$3.85M ﹤0.01% 3363
2025
Q2 		$5.77M Buy
391,386
+340,498
+669% +$3.97M ﹤0.01% 3017
2025
Q1 		$485K Sell
50,888
-13,902
-21% -$146K ﹤0.01% 4798
2024
Q4 		$805K Sell
64,790
-376,955
-85% -$3.88M ﹤0.01% 4773
2024
Q3 		$4.31M Sell
441,745
-953,120
-68% -$11.2M ﹤0.01% 3322
2024
Q2 		$22.5M Sell
1,394,865
-273,991
-16% -$4.95M ﹤0.01% 1780
2024
Q1 		$35.7M Buy
1,668,856
+738,654
+79% +$13.9M ﹤0.01% 1484
2023
Q4 		$14.2M Buy
930,202
+127,978
+16% +$2.27M ﹤0.01% 2137
2023
Q3 		$18.5M Sell
802,224
-168,399
-17% -$3.84M ﹤0.01% 1738
2023
Q2 		$23.1M Buy
+970,623
New +$22.2M ﹤0.01% 1594

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase's INDV Position: Q1 2026 in Review

JP Morgan Chase increased its Indivior Pharmaceuticals (INDV) stake by 156% in Q1 2026, buying an estimated $10.9M and bringing the position to 539,863 shares worth $15.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

JP Morgan Chase first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $35.7M in Q1 2024. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • JP Morgan Chase held 539,863 shares of Indivior Pharmaceuticals worth $15.5M as of Q1 2026.
  • JP Morgan Chase bought 328,655 Indivior Pharmaceuticals shares in Q1 2026, an estimated $10.9M.
  • Indivior Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2296 holding.
  • JP Morgan Chase first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • JP Morgan Chase's Indivior Pharmaceuticals position peaked at $35.7M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.